In the study of atezolizumab as first-line therapy in cisplatin-ineligible patients with locally advanced metastatic urothelial carcinoma, there was a significantly higher tumor mutation burden in patients who showed a response than in non-responders, with this finding being consistent across PD-L1 subgroups and TCGA subtypes [35]. The gene discussed is CD274; the disease is neoplasm.